Edition:
United Kingdom

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.59USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
79,473
52-wk High
$3.60
52-wk Low
$2.24

Chart for

About

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $92.37
Shares Outstanding(Mil.): 35.94
Dividend: --
Yield (%): --

Financials

  OPHT.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -5.39 -- --
ROI: -73.71 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Ophthotech Reports Posts Q4 Loss Of $0.26 Per Share

* OPHTHOTECH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

27 Feb 2018

BRIEF-Ophthotech Q3 earnings per share $5.25

* Ophthotech reports third quarter 2017 financial and operating results

08 Nov 2017

BRIEF-Ophthotech recieves termination notice from Novartis Pharma

* Ophthotech-On oct 24, co received from Novartis Pharma notice terminating Licensing & Commercialization Agreement between parties dated May 19, 2014 Source text : (http://bit.ly/2gPty5O) Further company coverage:

27 Oct 2017

Earnings vs. Estimates